SSA
CYTK icon

Schonfeld Strategic Advisors’s Cytokinetics CYTK Stock Holding History

Schonfeld Strategic Advisors’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-1,200
Closed -$65K – 2109
2024
Q2 		$65K Sell
1,200
-6,300
-84% -$380K ﹤0.01% 1911
2024
Q1 		$526K Buy
7,500
+3,700
+97% +$286K ﹤0.01% 1466
2023
Q4 		$317K Buy
+3,800
New +$138K ﹤0.01% 1415

Other funds holding CYTK

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Schonfeld Strategic Advisors's CYTK Position: Q1 2026 in Review

Schonfeld Strategic Advisors opened a new position in Cytokinetics (CYTK) in Q1 2026: 101,565 shares worth $6.69M. The stake represents 0.05% of the portfolio and ranks #407 among its holdings. This is a return to the name: Schonfeld Strategic Advisors previously reported a position in CYTK as recently as Q1 2025.

Schonfeld Strategic Advisors first reported a position in CYTK in Q3 2016 and has held it in 16 quarters since. The position peaked at $7.05M in Q1 2025. 439 funds tracked by Wall St. Rank hold CYTK as of Q1 2026.

  • Schonfeld Strategic Advisors held 101,565 shares of Cytokinetics worth $6.69M as of Q1 2026.
  • Cytokinetics was a new Schonfeld Strategic Advisors position in Q1 2026.
  • Cytokinetics made up 0.05% of Schonfeld Strategic Advisors's portfolio in Q1 2026, its #407 holding.
  • Schonfeld Strategic Advisors first reported a position in Cytokinetics in Q3 2016 and has held it in 16 quarters since.
  • Schonfeld Strategic Advisors's Cytokinetics position peaked at $7.05M in Q1 2025.
  • 439 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q1 2026, filed 15 May 2026.